Wall Street brokerages predict that Syndax Pharmaceuticals Inc (NASDAQ:SNDX) will post earnings per share (EPS) of ($1.02) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Syndax Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.20) and the highest estimate coming in at ($0.89). Syndax Pharmaceuticals reported earnings per share of ($0.71) in the same quarter last year, which suggests a negative year over year growth rate of 43.7%. The company is expected to issue its next quarterly earnings results on Monday, May 14th.
On average, analysts expect that Syndax Pharmaceuticals will report full year earnings of ($3.52) per share for the current year, with EPS estimates ranging from ($4.42) to ($2.63). For the next financial year, analysts anticipate that the firm will post earnings of ($3.50) per share, with EPS estimates ranging from ($5.02) to ($2.11). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Syndax Pharmaceuticals.
Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its earnings results on Monday, March 5th. The company reported ($0.80) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by ($0.04). The firm had revenue of $1.19 million during the quarter, compared to analysts’ expectations of $0.75 million. Syndax Pharmaceuticals had a negative net margin of 2,884.34% and a negative return on equity of 63.51%. The company’s quarterly revenue was up 290.2% compared to the same quarter last year.
Shares of SNDX stock traded up $0.18 during trading hours on Friday, reaching $10.57. The stock had a trading volume of 22,488 shares, compared to its average volume of 384,963. Syndax Pharmaceuticals has a 12 month low of $7.41 and a 12 month high of $15.43.
In related news, insider Peter Ordentlich sold 7,500 shares of Syndax Pharmaceuticals stock in a transaction on Tuesday, April 3rd. The shares were sold at an average price of $15.00, for a total value of $112,500.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 15.90% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of SNDX. BVF Inc. IL purchased a new position in Syndax Pharmaceuticals during the 4th quarter valued at $28,326,000. Millennium Management LLC increased its position in Syndax Pharmaceuticals by 18.9% during the 4th quarter. Millennium Management LLC now owns 516,500 shares of the company’s stock valued at $4,525,000 after purchasing an additional 82,256 shares during the period. Geode Capital Management LLC increased its position in Syndax Pharmaceuticals by 17.4% during the 4th quarter. Geode Capital Management LLC now owns 153,483 shares of the company’s stock valued at $1,344,000 after purchasing an additional 22,803 shares during the period. Crestline Management LP increased its position in Syndax Pharmaceuticals by 55.3% during the 4th quarter. Crestline Management LP now owns 83,139 shares of the company’s stock valued at $728,000 after purchasing an additional 29,607 shares during the period. Finally, State Street Corp increased its position in Syndax Pharmaceuticals by 32.8% during the 2nd quarter. State Street Corp now owns 81,327 shares of the company’s stock valued at $1,137,000 after purchasing an additional 20,106 shares during the period. 69.55% of the stock is currently owned by institutional investors.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.